9,154 Shares in GSK plc (NYSE:GSK) Bought by Virtu Financial LLC

Virtu Financial LLC acquired a new position in shares of GSK plc (NYSE:GSK) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 9,154 shares of the pharmaceutical company’s stock, valued at approximately $339,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Horizon Bancorp Inc. IN grew its stake in GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock worth $147,000 after buying an additional 323 shares during the last quarter. Cerity Partners LLC grew its stake in GSK by 305.7% during the 4th quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after buying an additional 89,089 shares during the last quarter. JPL Wealth Management LLC bought a new position in GSK during the 4th quarter worth $1,129,000. Dimensional Fund Advisors LP grew its stake in GSK by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock worth $65,883,000 after buying an additional 18,585 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of GSK in the fourth quarter worth $7,024,000. 15.74% of the stock is currently owned by institutional investors.

GSK Trading Up 0.7 %

Shares of GSK stock opened at $40.95 on Thursday. The stock has a 50-day simple moving average of $42.56 and a 200 day simple moving average of $41.03. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The stock has a market capitalization of $84.87 billion, a P/E ratio of 14.84, a P/E/G ratio of 1.23 and a beta of 0.66. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. On average, sell-side analysts expect that GSK plc will post 4.11 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.3762 dividend. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is currently 53.26%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on GSK. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target for the company. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.